Exhibit 99.1



Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update


CTA approved in Belgium and IND open in the U.S. for investigational drug candidate, ELX-02


On track to initiate Phase 2 clinical trials in cystic fibrosis and cystinosis in 2018


Expanded Leadership Team with Global Pharmaceutical Executives to Accelerate Growth


Company to host webcast and conference call on Tuesday, August 7, 2018 at 4:30 pm ET


Waltham, MA. – August 7, 2018 – Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis and other diseases caused by nonsense mutations limiting production of functional proteins, today reported its financial results for the three and six months ended June 30, 2018 and provided a business update.


“We are pleased to have achieved important regulatory milestones in Europe and the U.S. gaining clearance to initiate two Phase 2 clinical trials for our lead investigational product candidate, ELX-02, in cystic fibrosis and cystinosis, respectively. We are on track to initiate these this year and we are funded through data readouts,” said Robert E. Ward, Chairman and CEO of Eloxx Pharmaceuticals. “I am very gratified to have been successful in attracting experienced pharmaceutical executives to our leadership team who I am confident will add significant value as we build a high-performance culture committed to maximizing the value of ELX-02 and our library of novel compounds and pursue global collaborations.”


Recent Accomplishments


·Eloxx’s CTA for ELX-02 in cystic fibrosis has been approved by the Federal Agency for Medicines and Health Products (the “FAMHP”) in Brussels, Belgium. The European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN) has reviewed and approved our protocol for a Phase 2 clinical trial of ELX-02 in cystic fibrosis patients with a G542X mutation and has given it “high priority” status. We expect to initiate this trial in the fourth quarter of 2018.


The following information was filed by Eloxx Pharmaceuticals, Inc. (ELOX) on Tuesday, August 7, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Membership Level change

You have selected the Free membership level.

Get 7 days of FREE access to our online tools for reading 10-Ks and 10-Qs more efficiently:

  • Bullish, Bearish remarks
  • No advertisements
  • Disclosures
  • Wider reading area
  • Email notifications
  • Stock screener

The price for membership is $0.00 now.

Membership expires after 7 Days.

Account Information Already have an account? Log in here

Your privacy is important to us - We do not rent or sell your personal information
By creating an account, you are agreeing to our Terms and Privacy Policy

Log in with your credentials


Forgot your details?

Create Account